0001213900-24-034940 | 20-F/A | XBRL Viewer

SFr 6,331,282

^[1]

1,029,731

166,192

^[2]

(7,427,546)

Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]

99,659

Loans [Member]

5,869,797

^[1]

1,164,438

6,038,627

166,192

^[2]

(7,200,427)

(168,830)

Lease liabilities [Member]

5,869,797

Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]

461,485

575,736

^[1]

(134,707)

(130,200)

^[2]

(227,119)

15,949

Derivative financial instrument [Member]

SFr 99,659

461,485

Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]

1,233

^[1]

(1,233)

^[2]

Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]

Total [Member]

576,969

^[1]

5,908,427

(1,233)

^[2]

(152,881)

Schedule of Issued Share Capital [Line Items]

SFr 6,331,282

[1]	The financing cash flows are from loan borrowings or loan and lease repayments.
[2]	Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and remeasurement of lease liability.

Consolidated Statement of Financial Position	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)
Non-current assets
Property and equipment	SFr 1	SFr 1
Right-of-use assets	80,110	445,827
Intangible assets	3,893,681	3,893,681
Other non-current financial assets	80,001	194,263
Investment in an associate	2,417,312
Total non-current assets	6,471,105	4,533,772
Current assets
Inventories		11,644
Trade receivables		6,525
Other receivables	74,823	755,987
Prepayments	283,832	709,266
Derivative financial instruments	247,090	270,176
Cash and cash equivalents	617,409	15,395
Total current assets	1,223,154	1,768,993
Total assets	7,694,259	6,302,765
Equity
Share capital	2,646	236,011
Share premium	20,102,873	192,622,406
Other reserves	4,399,200	258,044
Accumulated deficit	(18,046,002)	(201,431,272)
Total shareholders’ (deficit)/equity attributable to owners of the Company	6,458,717	(8,314,811)
Non-current liabilities
Non-current lease liabilities		343,629
Employee benefit liability	346,628	336,206
Deferred income		932,200
Deferred tax liabilities		125,870
Total non-current liabilities	346,628	1,737,905
Current liabilities
Loan		5,869,797
Current lease liabilities	99,659	117,856
Trade and other payables	440,414	4,914,404
Accrued expenses	348,841	1,977,614
Total current liabilities	888,914	12,879,671
Total liabilities	1,235,542	14,617,576
Total equity and liabilities	SFr 7,694,259	SFr 6,302,765

Discontinued Operations (Details) - Schdule of Statement of Cash Flows - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schdule of Statement of Cash Flows [Abstract]
Operating activities	SFr (1,092,385)	SFr (1,104,053)	SFr (2,612,264)
Investing activities	67	67,406	(116,330)
Financing activities	1,056,532	859,610	2,000,000
Net cash from discontinued operations	SFr (35,786)	SFr (177,037)	SFr (728,594)

Deferred Income (Details) SFr in Millions	12 Months Ended
Deferred Income (Details) SFr in Millions	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)
Deferred Income [Abstract]
Upfront payment amount	SFr 0.9	$ 1,000,000
Deferred income			$ 0

Related Party Transactions (Details) - CHF (SFr)					3 Months Ended	12 Months Ended
Related Party Transactions (Details) - CHF (SFr)	May 31, 2023	May 01, 2023	Sep. 09, 2022	Feb. 04, 2022	Mar. 08, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions (Details) [Line Items]
Interest receivable						SFr 18,905
Agreement amount			SFr 600,000
Short term loan					SFr 100,000
Bearing interest rate	10.00%	4.99%		4.90%	5.00%
Share based payment charge amounted						283,588	SFr 223,286	SFr 240,408
Share based payments						283,588	223,286	240,408
Stock option amount						99,318	5,355	2,474
Gremaud GmbH [Member]
Related Party Transactions (Details) [Line Items]
Fees paid						251,110	195,988
Fees payment for other services						0	0
Dr Wickline [Member]
Related Party Transactions (Details) [Line Items]
Fees paid							172,512
Loan Agreement [Member]
Related Party Transactions (Details) [Line Items]
Agreement amount			SFr 200,000
Board of Directors Chairman [Member]
Related Party Transactions (Details) [Line Items]
Fees paid							138,507
Share based payment charge amounted						681,353
Payroll charge							1,038,810	810,671
Fees amount							183,058	165,245
Board of Directors [Member]
Related Party Transactions (Details) [Line Items]
Share based payment charge amounted						SFr 41,319	51,171	48,046
Pension amount							SFr 44,469	SFr 49,050	SFr 29,467

Capital and Reserves (Details) - Schedule of Issued Share Capital

Jan. 19, 2024

Dec. 31, 2023

CHF (SFr)

Dec. 31, 2023

USD ($)

Dec. 31, 2022

CHF (SFr)

Number

637,460

1,477,785

59,003

Value (CHF) (in Francs and Dollars)

SFr 2,646

$ 2,956

SFr 236,011

Ordinary Shares Nominal Value [member]

Schedule of Issued Share Capital [Line Items]

Number

^[1]

1,477,785

59,003

Value (CHF) (in Francs and Dollars)

^[1]

$ 2,956

SFr 236,011

[1]

The par value of the common shares was reduced from CHF 4.00 and changed to USD 0.0001 following approval the Company’s special general meeting of October 31, 2023, and subsequently the board of directors in December 2023 consolidated the then common shares of par value $0.0001 each at a ratio of 20:1, into common shares of par value $0.002 each. In total the share capital was reduced by CHF 2,903,684 to CHF 2,646 (USD 2,956) and the amount of the reduction was credited to share premium.

Financial Instruments and Risk Management (Tables)

12 Months Ended

Dec. 31, 2023

Financial instruments and risk management [Abstract]

Schedule of Carrying Amounts of Financial Assets and Financial Liabilities

The following table shows the carrying amounts of financial assets and financial liabilities:

	December 31,		December 31,
	2023		2022
Financial assets
At amortized cost
Cash and cash equivalents		617,409		15,395
Other non-current financial assets		80,001		194,263
Trade receivables		-		6,525
Other receivables		18,905		-
At fair value through profit and loss
Derivative financial instruments		247,090		270,176
Total financial assets		963,405		486,359

Financial liabilities
At amortized cost
Trade and other payables		440,413		4,914,404
Accrued expenses		348,841		1,977,614
Loan		-		5,869,797
Non-current lease liabilities		-		343,629
Current lease liabilities		99,659		117,856
At fair value through profit and loss
Derivative financial instruments		-		-
Total financial liabilities		888,913		13,223,300

Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities

The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2023 and 2022. The amounts disclosed in the table are the undiscounted cash flows:

					Between
	Carrying		Less than		3 months and		2 years and
	amount		3 months		2 years		later		Total
December 31, 2023
Trade and other payables		440,413		440,413		-		-		440,413
Accrued expenses		348,841		348,841		-		-		348,841
Loan and borrowings		-		-		-		-		-
Non-current lease liabilities		-		-		-		-		-
Current lease liabilities		99,659		33,677		67,354		-		101,031
Derivative financial instruments				-		-				-
Total		888,913		822,931		67,354		-		890,285

					Between
	Carrying		Less than		3 months and		2 years and
	amount		3 months		2 years		later		Total
December 31, 2022
Trade and other payables		4,914,404		4,914,404		-		-		4,914,404
Accrued expenses		1,977,614		1,977,614		-		-		1,977,614
Loan and borrowings		5,869,797		5,759,877		357,192		-		6,117,069
Non-current lease liabilities		343,629		-		130,200		227,850		358,050
Current lease liabilities		117,856		32,550		97,650		-		130,200
Derivative financial instruments				-		-				-
Total		13,223,300		12,684,445		585,042		227,850		13,497,337

Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques

	Fair values as at
	December 31,	December 31,	Fair value
Financial assets / liabilities	2023	2022	hierarchy	Valuation technique(s) and key input(s)
Derivative financial	Liability	Liability	Level 2	Black-Scholes option pricing model
liabilities – Warrants from public offerings	—	—		The share price is determined by Company’s NASDAQ quoted price.
				The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period.

Derivative financial liabilities – Embedded derivatives of 2023 FiveT Convertible (portion classified as liability)	Liability —	Liability —	Level 3	Black-Scholes option pricing model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates.

Derivative financial liabilities – Embedded derivatives of 2022 FiveT Convertible Loan	Liability —	Liability —	Level 3	Black-Scholes option pricing model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates.

Derivative financial asset - Option LPC purchase agreement	Asset 247,090	Asset 270,176	Level 3	The fair value is equal to the price paid to the counterparty for obtaining the right under the purchase agreement. The price paid corresponds to the fair value of 2,500 commitment shares issued to LPC as consideration for its commitment to purchase our common shares under the purchase agreement.
				Subsequent, the fair value is adjusted proportionally for the part of the right consumed through equity.

Schedule of Fair Value Measurement of Derivative Financial Instrument

						Non-cash changes
			Financing			Fair
			Cash			value		Other
	01.01.2023		Flows ¹⁾			revaluation		changes ²⁾			31.12.2023
Loans		5,869,797		1,164,438			166,192		(7,200,427	)		-
Lease liabilities		461,485		(134,707	)		-		(227,119	)		99,659
Total		6,331,282		1,029,731			166,192		(7,427,546	)		99,659

						Non-cash changes
			Financing			Fair
			Cash			value			Other
	01.01.2022		Flows ¹⁾			revaluation			changes ²⁾			31.12.2022
Derivative financial instrument		1,233		-			(1,233	)		-			-
Loans		-		6,038,627			-			(168,830	)		5,869,797
Lease liabilities		575,736		(130,200	)		-			15,949			461,485
Total		576,969		5,908,427			(1,233	)		(152,881	)		6,331,282

1)	The financing cash flows are from loan borrowings or loan and lease repayments.

2)	Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and remeasurement of lease liability.

Schedule of Carrying Amount of Each Financial Asset in the Consolidated Statement of Financial Position

The Company’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position:

	December 31,		December 31,
	2023		2022
Financial assets
Cash and cash equivalents		617,409		15,395
Other non-current financial assets		80,001		194,263
Trade receivables		-		6,525
Other receivables		18,905		-
Total		716,315		216,183

Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk

The summary of quantitative data about the exposure of the Company’s financial assets and liabilities to currency risk was as follows:

	2023								2022
in CHF	USD			EUR			AUD		USD			EUR			AUD
Cash and cash equivalents		7,637			2,652			-		1,791			3,462			-
Trade and other receivables		1,371,060			-			-		1,523,292			91,864			879,531
Trade and other payables		(129,943	)		(86,547	)		-		(1,086,206	)		(1,452,883	)		-
Accrued expenses		(91,355	)		(26,737	)		-		(220,616	)		(299,435	)		-
Net statement of financial position exposure -asset/(liability)		1,157,400			(110,632	)		-		218,261			(1,656,992	)		879,531

Other Receivables (Details)	Dec. 31, 2023 CHF (SFr)
Other Receivables [Abstract]
Receivable from suppliers	SFr 18,905

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Share Based Compensation [Abstract]

Schedule of Key Terms and Conditions Related to the Grants

The key terms and conditions related to the grants under these programs at December 31, 2023 are as follows:

	Number of			Contractual
	options			life of
Plan	outstanding		Vesting conditions	options
Equity Incentive Plan Board		7,898	1 year service from grant date	6 years
Equity Incentive Plan Management & Staff		68,713	2 years’ service from grant date (50%)	8 years
Equity Incentive Plan Management & Staff		68,713	3 years’ service from grant date (50%)	8 years

Schedule of Fair Value of the Options Measured

The fair value of the options was measured based on the Black-Scholes formula.

	Stock Option Plan
	Equity Incentive	Equity Incentive	Equity Incentive	Equity Incentive
	Plan 2023	Plan 2023	Plan 2022	Plan 2022
Fair value at grant date	USD 1.72 (2 year vesting) ¹⁾ USD 1.96 (3 year vesting) ¹⁾	USD 6.674 (1 year vesting) 2) USD 10.918 (2 year vesting) ²⁾ USD 12.82 (3 year vesting) ²⁾	USD 86.94 (2 year vesting) ¹⁾ USD 100.22 (3 year vesting) ¹⁾	USD 132.88 (1 year vesting) ²⁾ USD 175.2 (2 year vesting) ²⁾ USD 212.08 (3 year vesting) ²⁾

Share price at grant date	USD 2.92	USD 19.2	USD 149.6	USD 356
Exercise price	USD 2.92	USD 19.2	USD 127.06	USD 415.60
Expected volatility	108.87%	111.23%	100.2%	99.1%
Expected life	2 and 3 years	1, 2 and 3 years	2 and 3 years	1, 2 and 3 years
Expected dividends	—	—	—	—
Risk-free interest rate	4.90%	4.37%	4.45%	2.87%

1)	October grants for the respective year

2)	April grants for the respective year

Schedule of Exercise Prices for Outstanding Options

The range of exercise prices for outstanding options was CHF 2.46 to CHF 10,637 as of December 31, 2023 and CHF 117.6 to CHF 11,693.20 as of December 31, 2022.

	2023							2022
				Weighted		Weighted					Weighted		Weighted
				average		average					average		average
	Number of			exercise		remaining		Number of			exercise		remaining
	options			price		term		options			price		term
Outstanding at January 1		7,884			385.60		6.22		3,324			660.00		6.56
Expired during the year		-			-		-		-			-		-
Forfeited during the year		(1,467	)		-		-		(325	)		-		-
Exercised during the year					-		-		-			-		-
Granted during the year		138,907			4.76		-		4,885			188.00		-
Outstanding at December 31		145,324			22.17		5.62		7,884			385.60		6.22
Exercisable at December 31		2,630			-		-		1,440			-		-

Intangible Assets

12 Months Ended

Dec. 31, 2023

Intangible Assets [Abstract]

Intangible assets

9. Intangible assets

				IP & Data						Internally
	Licenses			rights			Patents			generated			Total
At cost
As of January 1, 2022		5,376,201			193,989			473,154			9,801,462			15,844,806
Exchange differences		-			-			-			-			-
Additions		-			-			275,281			1,700,503			1,975,784
As of December 31, 2022		5,376,201			193,989			748,435			11,501,965			17,820,590
Exchange differences		-			-			-			168			168
Additions		-			-			-			-			-
As of December 31, 2023		5,376,201			193,989			748,435			11,502,133			17,820,758

Accumulated amortization and impairment losses
As of January 1, 2022		(1,482,520	)		(47,409	)		-			-			(1,529,929	)
Impairment					(146,580	)		(748,435	)		(11,502,133	)		(12,397,148	)
As of December 31, 2022		(1,482,520	)		(193,989	)		(748,435	)		(11,502,133	)		(13,927,077	)
Impairment		-			-			-			-			-
As of December 31, 2023		(1,482,520	)		(193,989	)		(748,435	)		(11,502,133	)		(13,927,077	)

Net book value
As of December 31, 2022		3,893,681			-			-			-			3,893,681
As of December 31, 2023		3,893,681			-			-			-			3,893,681

Intangible assets comprise upfront and milestone payments related to licenses and capitalized development costs.

Commencing with the business year 2018, the Company recorded intangibles related to direct development expenditure of its AM-125 program. In 2019, a US patent on AM-125 was issued and a related EU application was allowed. As a consequence, we started to capitalize patent prosecution and registration costs until and including the year 2022, where CHF 275,281 for patents and CHF 1,700,503 of internal development costs were capitalized.

Based on the impairment testing performed under IFRS as of December 31, 2022, all intangible assets related to the AM-125 project were written off. Accordingly, in the year 2022 the Company recorded an impairment of CHF 12,397,148 to its recoverable amount for AM-125 taking in consideration uncertainties regarding the realization of the cash flows in connection with the planned sale or the out-licensing of the AM-125 assets. The recoverable amount was calculated based on an out-license model of AM-125 at current development stage. The recoverable amount of the relevant intangible asset has been determined to be nil on the basis of their value in use, with consideration of fair value less costs of disposal not supporting a higher recoverable amount. In the year 2023 no development costs were capitalized.

As at December 31, 2023, intangible assets only include a license. The license is related to the acquisition of Trasir Therapeutics Inc. in 2021, which was treated as an asset acquisition because substantially all the fair value of Trasir was concentrated in a worldwide exclusive license agreement with Washington University (Note 3). Amortization will commence once the intangible assets are available for use, which will be the case after regulatory approvals are obtained and the related products are available for use.

Warrants from Public Offering (Details)				12 Months Ended
Warrants from Public Offering (Details)	Dec. 15, 2023 shares	Jul. 10, 2023 SFr / shares shares	Jul. 10, 2023 $ / shares shares	Dec. 31, 2023 CHF (SFr) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 shares
Warrants from Public Offering [Line items]
Public offering				555,556	555,556
Pre funded warrants		511,806	511,806
Common shares	81,274	555,556	555,556	81,274	81,274
Public offering price (in Dollars per share) \| (per share)		SFr 9	$ 9
Exercise price warrants (in Francs per share) \| SFr / shares		SFr 8
Warrants granted		36,113	36,113
Strike price (in Francs per share) \| SFr / shares		SFr 10
Exercise period		5 years	5 years
Pre-funded warrants were exercised (in Dollars) \| $					$ 112,597
Value of warrants and prefunded warrants (in Francs) \| SFr
Gross proceed offering cost				4,444,445	5,000,000
Attributable transaction costs				SFr 198,246	$ 728,728
Fair value assumptions volatility				107.34%	107.34%
Annual risk-free rate				4.25%	4.25%
CHF [Member]
Warrants from Public Offering [Line items]
Warrants issued				3,921,647	3,921,647
Warrants [Member]
Warrants from Public Offering [Line items]
Public offering		43,750	43,750
Warrants granted		36,113	36,113
Value of warrants and prefunded warrants (in Francs)				SFr 102,361	$ 112,597
Attributable transaction costs \| SFr				SFr 639,873

Taxation (Details) SFr in Millions		12 Months Ended
Taxation (Details) SFr in Millions	May 04, 2023	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Taxation [Line items]
Weighted average tax rate	90.00%	15.80%	13.70%	13.50%
Unrecognized tax loss carryforwards \| $					$ 60,606,571	$ 103,114,677
Auris Medical AG [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards		SFr 60.6	SFr 101.4
Otolanum AG [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards			103.1
Altamira Therapeutics AG [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards		59.0
Altamira Therapeutics Inc [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards		SFr 1.6
Auris Medical Inc [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards			SFr 1.7

Warrants from Public Offering

12 Months Ended

Dec. 31, 2023

Warrants from Public Offering [Abstract]

Warrants from Public Offering

31. Warrants from Public Offering

On July 10, 2023, the Company closed a public offering of 43,750 common shares and 511,806 pre-funded warrants and accompanying common warrants to purchase up to 555,556 common shares, at a combined public offering price of $9.00 per share, pre-funded warrant and accompanying common warrant. The common warrants have an exercise price of CHF 8.00 per share, are exercisable immediately and expire five years from the date of issuance. The Company additionally granted 36,113 warrants to the Placement Agent with a strike price of CHF 10.0 and an exercise period of 5 years. As of December 31, 2023, all pre-funded warrants have been exercised for a total amount of $112,597 (CHF 102,361). The total gross proceeds from the offering amounted to $5,000,000 (CHF 4,444,445). Directly related transaction costs of $ 728,728 (CHF 639,873) were recorded as a deduction in equity. The fair value of each of the warrants issued was calculated using the Black-Scholes valuation model. The fair value calculation assumptions included volatility of 107.34 % and an annual risk-free rate of 4.25%. The total fair value of the warrants issued amounted to CHF 3,921,647 and has been recorded in equity as a cost of the offering.

Reporting Entity

12 Months Ended

Dec. 31, 2023

Reporting Entity [Abstract]

Reporting entity

1. Reporting entity

Altamira Therapeutics Ltd. (the “Company”) is an exempted company incorporated under the laws of Bermuda. The Company began its operations as a corporation organized in accordance with Swiss law and domiciled in Switzerland under the name Auris Medical Holding AG (“Auris Medical (Switzerland)”). Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). On March 18, 2019, the common shares of the Company began trading on the Nasdaq Capital Market under the trading symbol “EARS”. The Company’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”. On December 13, 2023, the Company effected a one-for-twenty reverse share split (the “2023 Reverse Share Split”) of the Company’s issued and outstanding common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2023 Reverse Share Split, as if such 2023 Reverse Share Split occurred on the first day of the periods presented.

These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Company” and individually as “Company entities”). The Company is the ultimate parent of the following Company entities:

●

Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000

●

Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Altamira Therapeutics AG, Zug, Switzerland (100%), with a nominal share capital of CHF 100,000

●

Altamira Medica AG, Zug, Switzerland (49%), with a nominal share capital of CHF 3,000,000 ¹⁾

●

Altamira Therapeutics, Inc., Newark, Delaware, United States (100%) with a nominal share capital of $100

●

Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100

●

Auris Medical Pty Ltd, Melbourne, Australia (49%), with a nominal share capital of AUD 100 ¹⁾

¹⁾

On November 21, 2023, the Company divested partially its Bentrio® business by selling a 51% stake in Altamira Medica AG, Zug, Switzerland, and its 100% subsidiary Auris Medical Pty Ltd, Melbourne, Australia. After the sale, the retained 49% stake is accounted for as investment in an associate using the equity method.

Altamira is a preclinical-stage biopharmaceutical company developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). It currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In 2023 the Company took a first step in its repositioning around the RNA delivery business by spinning off a 51% stake in Altamira Medica AG, which manufactures and markets Bentrio®, an OTC nasal spray for allergic rhinitis. The Company intends to partner / divest also its AM-125 program, a nasal spray for vertigo (post Phase 2), as well as its early- to late-stage clinical development programs in tinnitus and hearing loss.

Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Investment [Abstract]

Schedule of Inventories

	December 31,		December 31,
	2023		2022
Finished goods		-		11,644
Total		-		11,644

Share-Based Compensation

12 Months Ended

Dec. 31, 2023

Share Based Compensation [Abstract]

Share-based compensation

16. Share-based compensation

Description

In 2014, the Company introduced an equity incentive plan (the (“EIP”), which was amended in 2017 and 2019. In 2023, the Company granted 138,907 options (2022: 4,885 options) under the EIP.

Holders of vested options are entitled to purchase common shares of the Company. Under the Equity Incentive Plan, the Board of Directors defined the exercise price as the average daily closing price of the Company’s shares during the 30 days preceding the date of grant. All options are to be settled by the physical delivery of shares. The key terms and conditions related to the grants under these programs at December 31, 2023 are as follows:

	Number of			Contractual
	options			life of
Plan	outstanding		Vesting conditions	options
Equity Incentive Plan Board		7,898	1 year service from grant date	6 years
Equity Incentive Plan Management & Staff		68,713	2 years’ service from grant date (50%)	8 years
Equity Incentive Plan Management & Staff		68,713	3 years’ service from grant date (50%)	8 years

Measurement of fair values

The fair value of the options was measured based on the Black-Scholes formula.

	Stock Option Plan
	Equity Incentive	Equity Incentive	Equity Incentive	Equity Incentive
	Plan 2023	Plan 2023	Plan 2022	Plan 2022
Fair value at grant date	USD 1.72 (2 year vesting) ¹⁾ USD 1.96 (3 year vesting) ¹⁾	USD 6.674 (1 year vesting) 2) USD 10.918 (2 year vesting) ²⁾ USD 12.82 (3 year vesting) ²⁾	USD 86.94 (2 year vesting) ¹⁾ USD 100.22 (3 year vesting) ¹⁾	USD 132.88 (1 year vesting) ²⁾ USD 175.2 (2 year vesting) ²⁾ USD 212.08 (3 year vesting) ²⁾

Share price at grant date	USD 2.92	USD 19.2	USD 149.6	USD 356
Exercise price	USD 2.92	USD 19.2	USD 127.06	USD 415.60
Expected volatility	108.87%	111.23%	100.2%	99.1%
Expected life	2 and 3 years	1, 2 and 3 years	2 and 3 years	1, 2 and 3 years
Expected dividends	—	—	—	—
Risk-free interest rate	4.90%	4.37%	4.45%	2.87%

1)	October grants for the respective year

2)	April grants for the respective year

The Company uses its own historic volatility to calculate expected volatility. The expected life of all options is assumed to correspond to the vesting period.

The total expense recognized for equity-settled share-based payment transactions were CHF 379,414 in 2023 (2022: CHF 342,799, 2021: CHF 1,206,303).

The number and weighted average exercise prices (in CHF) of options under the share option programs are as follows:

The range of exercise prices for outstanding options was CHF 2.46 to CHF 10,637 as of December 31, 2023 and CHF 117.6 to CHF 11,693.20 as of December 31, 2022.

	2023							2022
				Weighted		Weighted					Weighted		Weighted
				average		average					average		average
	Number of			exercise		remaining		Number of			exercise		remaining
	options			price		term		options			price		term
Outstanding at January 1		7,884			385.60		6.22		3,324			660.00		6.56
Expired during the year		-			-		-		-			-		-
Forfeited during the year		(1,467	)		-		-		(325	)		-		-
Exercised during the year					-		-		-			-		-
Granted during the year		138,907			4.76		-		4,885			188.00		-
Outstanding at December 31		145,324			22.17		5.62		7,884			385.60		6.22
Exercisable at December 31		2,630			-		-		1,440			-		-

Employee Benefits (Details) - Schedule of Defined Benefit Plan Expense Recognized in Profit or Loss - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Defined Benefit Plan Expense Recognized in Profit or Loss [Abstract]
Salaries	SFr 2,145,943	SFr 2,815,411	SFr 1,865,633
Pension costs	172,460	266,256	165,801
Other social benefits	293,753	294,017	275,258
Share based payments costs	379,414	342,799	1,223,696
Other personnel expenditures	9,999	2,024	214,940
Total employee benefits	3,001,569	3,720,507	3,745,328
Employee benefits attributable to continuing operations	2,243,955	2,071,436	2,375,668
Employee benefits attributable to discontinued operations	SFr 757,614	SFr 1,649,071	SFr 1,369,660

Finance Income and Finance Expense

12 Months Ended

Dec. 31, 2023

Finance Income and Finance Expense [Abstract]

Finance income and finance expense

24. Finance income and finance expense

	2023			2022			2021
Interest income		302,249			114,268			26,990
Net foreign currency exchange gain		-			-			47,161
Revaluation gain from derivative financial instruments		15,066			451,131			5,085
Gain on modification of financial instruments		36,778			-			-
Total finance income		354,093			565,399			79,236
Interest expense (incl. bank charges)		1,032,444			904,345			14,112
Net foreign currency exchange loss		447,456			305,560			-
Revaluation loss from derivative financial instruments		181,258			-			-
Loss on modification of financial instruments		7,317			-			-
Transaction costs		-			1,137			-
Total finance expense		1,668,475			1,211,042			14,112
Finance expense, net		(1,314,382	)		(645,643	)		65,124

Revised for the reclassification of certain activities as discontinued operations in 2022 and 2021 – refer to Notes 1, 10 and 27.

In 2023, the revaluation gain from derivative financial instruments of CHF 15,066 relates to the fair value change of warrants attached to the 2023 FiveT convertible loan. The revaluation loss from derivative financial instruments of CHF 181,258 is related to the revaluation of the financial derivatives embedded in the 2022 FiveT convertible loan at conversion. The gain and loss on modification of financial instruments of CHF 36,778 and CHF 7,317 respectively, were realized on the modification of loans with warrants. In 2022, the revaluation gain from derivative financial instruments of CHF 451,131 includes CHF 449,898 related to the revaluation of the financial derivatives embedded in the 2022 FiveT convertible loan and CHF 1,233 related to the revaluation of outstanding warrants from public offerings.

Total interest expense recognized using the effective interest rate method amounted to CHF 1,007,437 in 2023, CHF 892,005 in 2022 and CHF 4,991 in 2021.

Capital and Reserves (Details) - Schedule of Common Shares - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Common Shares [Line Items]
Beginning balance	59,003	37,411
Exercise of warrants	81,274
Public Offering	555,556
LPC equity line	17,500	15,750
ATM program	104,147	5,842
Conversion convertible loans	660,345
Fractional shares eliminated upon reverse split	(40)
Ending balance	1,477,785	59,003

Material Accounting Policies (Details)	12 Months Ended
Material Accounting Policies (Details)	Dec. 31, 2023 CHF (SFr) SFr / shares shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Jun. 01, 2021
Significant Accounting Policies [Line items]
Share capital percentage					100.00%
Common shares (in Shares) \| shares	1,911	1,911
Common shares per share (in Francs per share) \| SFr / shares	SFr 4
Average closing price (in Dollars) \| $		$ 1,500,000
Common trading days	15 days	15 days
Reference price (in Dollars) \| $		$ 1,308
Expenses incurred (in Dollars) \| $		$ 210,000
Cash paid	SFr 617,409		SFr 15,395
Minimum royalty term	12 years	12 years
Aggregate amount (in Dollars) \| $		$ 4,375,000
Estimated fair value	SFr (29,461)
License acquired amounted	3,893,681		SFr 3,893,681
Attributable transaction costs	198,246	$ 728,728
Leases amount	SFr 5,000
Granted share option percentage	50.00%	50.00%
Granted term	2 years	2 years
Tax offset percentage	43.50%	43.50%
Research and development expenditures percentage	48.50%	48.50%
Equity Incentive Plan [Member]
Significant Accounting Policies [Line items]
Granted term	3 years	3 years
Remaining granted percentage	50.00%	50.00%
Common Shares [Member]
Significant Accounting Policies [Line items]
Average closing price (in Dollars) \| $		$ 2,500,000
Cash paid	SFr 180,000
License [member]
Significant Accounting Policies [Line items]
Estimated useful life	10 years	10 years
Board of Directors [Member]
Significant Accounting Policies [Line items]
Granted term	1 year	1 year
Fair value [Member]
Significant Accounting Policies [Line items]
Estimated fair value	SFr 269,700

Commitments and Contingencies (Details) - CHF (SFr)	12 Months Ended
Commitments and Contingencies (Details) - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Commitments and contingencies [Line Items]
Office lease expenses	SFr 6,600	SFr 6,001

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Low Value and Short-Term Lease Expenses - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Low Value and Short Term Lease Expenses [Abstract]
Expense related to short-term leases	SFr 6,600	SFr 6,001
Expense related to leases of low value assets
Total	SFr 6,600	SFr 6,001

Cash and Cash Equivalents

12 Months Ended

Dec. 31, 2023

Cash and Cash Equivalents [Abstract]

Cash and cash equivalents

14. Cash and cash equivalents

	December 31,		December 31,
	2023		2022
Cash in bank accounts		617,409		15,395
Cash on hand		-		-
Total cash and cash equivalents		617,409		15,395

Employee Benefits (Details) - CHF (SFr)	12 Months Ended
Employee Benefits (Details) - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Benefits [Abstract]
Interest rate term	2 years
Benefit plans interest rate	1.00%	1.00%	1.00%
Weighted average duration defined benefit obligation	17 years 8 months 12 days	17 years 1 month 6 days
Expected employer plam	SFr 128,608

Loss Per Share (Details) - Schedule of Loss Per Share (Parentheticals) - SFr / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Loss Per Share [Abstract]
Diluted loss per share	SFr (7.88)	SFr (582.58)	SFr (515.11)
Diluted loss per share	SFr (14.80)	SFr (409.60)	SFr (201.97)

Material Accounting Policies

12 Months Ended

Dec. 31, 2023

Significant Accounting Policies [Abstract]

Material accounting policies

3. Material accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated.

Basis of consolidation

Subsidiaries

Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

Transactions eliminated on consolidation

All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Segment reporting

A segment is a distinguishable component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company’s other components.

The Chief Executive Officer is determined to be the Company’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Company as a whole, as all of the Company’s activities are focusing on the development of therapeutics for important unmet medical needs. Financial information is only available for the Company as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.

Foreign currency

Foreign currency transactions

Items included in the financial statements of Company entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated.

Foreign operations

Assets and liabilities of Company entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction).

These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal.

Closing rates for the most significant foreign currencies relative to CHF:

		Geographical	Reporting	December 31,		December 31,
Currency		area	entities	2023		2022
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000
USD	Dollar	United States	1		0.8451		0.9251
EUR	Euro	Europe	1		0.9287		0.9901
AUD	Dollar	Australia	1		0.5735		0.6305

Average exchange rates for the year for the most significant foreign currencies relative to CHF:

		Geographical	Reporting
Currency		area	entities	2023		2022
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000
USD	Dollar	United States	1		0.8985		0.9550
EUR	Euro	Europe	1		0.9721		1.0050
AUD	Dollar	Australia	1		0.5971		0.6629

Property and equipment

Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows:

Production equipment			5 years
Office furniture and electronic data processing equipment (“EDP”)			3 years

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use.

Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.

Intangible assets

Research and development

Expenditures on the Company’s research programs are not capitalized, they are expensed when incurred.

Expenditures on the Company’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Company, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it was the Company’s assessment up to 2022 that the criteria mentioned above were met and therefore direct development expenditures were capitalized for AM-125 in 2021 and 2022, including intellectual property-related costs for the prosecution and registration of patents. As of December 31, 2022, all capitalized direct development costs related to AM-125 were impaired based on the impairment test performed under IFRS. The impairment was recognized as an R&D expense in 2022.

Licenses, intellectual property and data rights

Intellectual property rights that are acquired by the Company are capitalized as intangible assets if they are controlled by the Company, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets.

Measurement

Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

Amortization

All licenses of the Company have finite lives. Amortization will commence once the Company’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Company assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.

Impairment of non-financial assets

Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.

Asset purchase

On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery.

The purchase price for Trasir comprised: (i) 1,911 non-registered common shares of the Company, par value CHF 4.00 per share, calculated based on a value of $2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to $1,308 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), $1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) $210,000 for expenses incurred by certain selling Trasir shareholders paid in $180,000 in cash and 23 non-registered common shares based on the Reference Price.

Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of $4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license.

The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2022 and December 31, 2023, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.

Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Company recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment.

Lease liabilities

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

Short-term leases and leases of low-value assets

The Company applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.

Associates

Where the Company has the power to participate in (but not control) the financial and operating policy decisions of another entity, it is classified as an associate. Associates are initially recognized in the consolidated statement of financial position at cost. An investment in an associate that represents the retained interest in a former subsidiary is recognized at its fair value at the date when control is lost. Subsequently associates are accounted for using the equity method, where the Company’s share of post-acquisition profits and losses and other comprehensive income is recognized in the consolidated statement of profit and loss and other comprehensive income (except for losses in excess of the Company’s investment in the associate unless there is an obligation to make good on those losses).

Profits and losses arising on transactions between the Company and its associates are recognized only to the extent of unrelated investors’ interests in the associate. The investor’s share in the associate’s profits and losses resulting from these transactions is eliminated against the carrying value of the associate.

Any premium paid for an associate above the fair value of the Company’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the associate. Where there is objective evidence that the investment in an associate has been impaired the carrying amount of the investment is tested for impairment in the same way as other non-financial assets.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

Discontinued operations

A discontinued operation is a component of the Company’s business that represents a separate major line of business or geographical area of operations or is a subsidiary acquired exclusively with a view to resale, that has been disposed of, has been abandoned or that meets the criteria to be classified as held for sale.

Discontinued operations are presented in the consolidated statement of comprehensive income/(loss) as a single line which comprises the post-tax profit or loss of the discontinued operation along with the post-tax gain or loss recognized on the re-measurement to fair value less costs to sell or on disposal of the assets or disposal Companies constituting discontinued operations.

When an operation is classified as a discontinued operation, the comparative statement of profit or loss is re-presented as if the operation had been discontinued from the start of the comparative year. The objective is to provide the users of the financial statements with the most useful information to evaluate the financial effects of discontinued operations. Transactions between continuing and discontinued operations are presented as part of the respective continuing or discontinued operations. For the divested Bentrio business, this approach best reflects the continuance of the relationship. However, intragroup transactions between continuing and discontinued operations are eliminated in the financial statements as a whole.

Financial instruments

The Company classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Recognition and derecognition of non-derivative financial assets and liabilities

The Company initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date.

The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Company is recognized as a separate asset or liability.

The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired.

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

Non-derivative financial assets and liabilities—measurement

Loans and receivable

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses.

Cash and cash equivalents

The Company considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents.

Non-derivative financial liabilities—measurement

Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

Convertible loans

In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method.

Share capital

All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement.

The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Impairment of non-derivative financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment.

Objective evidence that financial assets are impaired includes:

●

default or delinquency by a debtor;

●

indications that a debtor or issuer will enter bankruptcy;

●

adverse changes in the payment status of borrowers or issuers;

●

the disappearance of an active market for a security; or

●

observable data indicating that there is measurable decrease in expected cash flows from a Company of financial assets.

Financial assets measured at amortized cost

The Company considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.

Derivative Financial Instruments

Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. At each period-end, relative to the portion of shares sold under the contract, a portion of the option value is derecognized to equity.

Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss.

Embedded Derivatives

Derivatives may be embedded in another contractual arrangement. The Company accounts for an embedded derivative separately from the host contract when:

The host contract is not an asset in the scope of IFRS 9

The host contract is not itself carried at fair value through profit and loss (FVPL)

The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract

The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host

The separated embedded derivative in the 2022 FiveT convertible loan was initially measured at fair value by an independent consultant applying a simulation-based valuation approach. On December 31, 2022, the embedded derivative was measured based on the Black-Scholes option pricing model, resulting in a fair value of zero. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss.

The 2023 FiveT convertible loan was classified as a compound financial instrument containing a host liability and two equity components (conversion right and warrants). The fair value of the liability component was determined first by discounting the future cash flows at the rate of interest that would apply to an identical financial instrument without these features. The equity components were measured at the residual amount, by deducting the amount calculated for the liability component from the fair value of the instrument as a whole. The residual amount was allocated to the two equity components based on their relative fair values. The host liability was subsequently measured at amortized cost, using the effective interest rate method.

Income tax

Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date.

Deferred tax

Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for:

●

temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss;

●

temporary differences related to investments in subsidiaries to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and

●

taxable temporary differences arising on the initial recognition of goodwill.

Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its tax assets and liabilities on a net basis.

Employee benefits

The Company maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States.

The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

Share-based compensation

The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations.

The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Company’s Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.

The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium.

Valuation of share options

Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.

Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Revenue recognition

The Company recognizes revenue from the license of intellectual property and from the sale of products. To assess revenue recognition for arrangements that the Company determines are within the scope of IFRS 15, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the services promised within each contract and determine those that are performance obligations and assess whether each promised service is distinct.

License of intellectual property

The Company recognizes as revenue its non-refundable license fees, milestone payments and royalties when its customer obtains control of promised services, in an amount that reflects the consideration which the Company expects to receive in exchange for those rendered services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues when the license conveys a right of use, or there is a right of access to the underlying intellectual property. However, revenue for a license that provides a right to use the Company’s intellectual property before the beginning of the period during which the customer is able to use and benefit from the license is deferred. Revenue from sales-based royalty, in exchange for a license of intellectual property is recognized only when the subsequent sale occurs and the performance obligation to which the sales-based royalty has been allocated has been satisfied (in whole or in part).

Sale of products

Up to the partial divestiture of the Bentrio Business on November 21, 2023, the Company sold a single product, Bentrio®, a drug-free nasal spray for protection against airborne viruses and allergens. Due to the partial divestiture of the Bentrio® business, revenue from Bentrio® sales in 2023 and 2022 is presented as part of the result from discontinued operations. Revenue from sale of products is recognized at the point in time when control of the asset is transferred to the customer, generally on delivery of the product if no other agreement has been made. Revenue is net of value-added tax, rebates, discounts and returns.

Government grants

Government grants are not recognized until there is reasonable assurance that the Company will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related research and development costs for which the grants are intended to compensate. Government grants that are receivable as compensation for expenses already incurred are recognized in profit or loss in the period in which they become receivable. The income from grants related to R&D expenditures are presented separately under the heading of ‘other operating income’. Grants that relate to the acquisition of an asset are recognized in profit or loss as the asset is depreciated or amortized. These grants are recognized as a reduction in the cost of the asset.

Auris Medical Pty Ltd obtains credits under the Australian R&D Tax Incentive program (R&DITC) which are reported under discontinued operations. The program provides a tax offset of 43.5% of eligible R&D expenditures if the company qualifies as a Base Rate Entity (“BRE”), or a tax offset of 48.5% if the company is not a BRE. The assessment is carried out annually and the calculation of tax credits available are adjusted accordingly. If the tax offset exceeds the Company’s tax liability, the balance is paid in cash after submission of a valid claim. Based on the specific features of the program, IAS 20 Government Grants is applied for the accounting treatment of the Australian R&DITC. The reimbursement application is made by the Company annually, once the fiscal year is closed, based on the financial statements.

Altamira Therapeutics Inc (former Trasir Therapeutics Inc) has obtained a grant from the NIH National Institutes of Health, to compensate for R&D expenses related to the development of “a Peptide-Based Polyplex Platform for Nucleotides Delivery to the Sites of Inflammation”. The income from the NIH grant which is related to R&D expenditures is recognized in profit or loss as other operating income (refer to Note 20).

Earnings/(loss) per share

Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares. Earnings/(loss) per share is calculated on the net profit/(loss) attributable to owners of the company as a whole and to continuing and discontinued operations (refer to notes 26 and 27).

Accrued Expenses (Details) - Schedule of Accrued Expenses - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Accrued Expenses [Abstract]
Accrued research and development costs including milestone payments	SFr 87,522	SFr 741,291
Professional fees	17,412	326,365
Accrued vacation & overtime	52,368	46,868
Employee benefits incl. share based payments	190,610	362,497
Accrued interest		457,812
Other	929	42,781
Total accrued expenses	SFr 348,841	SFr 1,977,614

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Lease Liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Lease Liabilities [Abstract]
Beginning Balance	SFr 461,485	SFr 575,736
Additions
Interest expense	19,294	15,949
Repayment of lease liability	(134,707)	(130,200)
Remeasurement (revised lease term)	(246,413)
Ending Balance	99,659	461,485
thereof non-current		343,629
thereof current	SFr 99,659	SFr 117,856

Employee Benefits (Details) - Schedule of Defined Benefit Cost and Liability Assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Defined Benefit Cost and Liability Assumptions [Abstract]
Service cost	SFr 163,101	SFr 256,336	SFr 159,085
Net interest expense	3,270	1,575	1,878
Administration expense	4,259	5,369	6,030
Total defined costs for the year recognized in profit or loss	170,630	263,280	166,993
Actuarial loss (gain) arising from changes in financial assumptions	247,262	(876,841)	(74,284)
Actuarial loss (gain) arising from experience adjustments	(138,497)	(54,795)	463,238
Actuarial gain arising from demographic assumptions	(3,905)		(229,109)
Return on plan assets excluding interest income	(136,023)	490,359	(424,829)
Total defined benefit cost for the year recognized in other comprehensive income	SFr (31,163)	SFr (441,277)	SFr (264,984)
Discount rate	1.50%	2.20%	0.30%
Future salary increases	1.35%	1.60%	0.85%
Pension indexation	0.00%	0.00%	0.00%
Mortality and disability rates	BVG2020	BVG2020	BVG2020

Intangible Assets (Details)	12 Months Ended
Intangible Assets (Details)	Dec. 31, 2022 CHF (SFr)
Intangible Assets [Abstract]
Capitalized amount	SFr 275,281
Internal development costs	1,700,503
Impairment	SFr 12,397,148

Inventories (Details) - Schedule of Inventories - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventories [Abstract]
Finished goods		SFr 11,644
Total		SFr 11,644

Other Operating Income (Details) - Schedule of Other Operating Income - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Operating Income [Abstract]
Income from Government grants	SFr 228,302
Other income	27,287	9,327
Total other operating income	SFr 255,589	SFr 9,327

Investment in an Associate

12 Months Ended

Dec. 31, 2023

Investment in an Associate [Abstract]

Investment in an associate

10. Investment in an associate

On November 21, 2023 the Company closed the transaction for the partial divestiture of its Bentrio® business, by selling a 51% stake in its subsidiary Altamira Medica AG (“Medica”). The transaction also includes the sale of Auris Medical Pty Ltd, Melbourne (Australia), a wholly owned subsidiary of Altamira Medica AG. The two companies sold represent the entirety of the Bentrio® business and are presented as discontinued operations.

Until the date of the transaction, Altamira Medica AG and Auris Medical Pty Ltd., Melbourne (Australia), were fully consolidated as the Company had control of these wholly owned subsidiaries. Following the sale, the new owner holds the majority of the voting rights and may appoint a majority of the Board of Directors of Medica. As a result of the transaction the Company has lost control but has the power to participate in the financial and operating policy decisions of its former subsidiary. Therefore, the retained share of 49% in Medica is accounted for as investment in an associate using the equity method.

Further, the transaction included a cash contribution of CHF 1,000,000 in total to Altamira Medica’s capital by its two shareholders pro rata of their shareholdings following the closing. Accordingly, the Company has contributed CHF 490,000 in cash to its investment in Altamira Medica.

The following table illustrates the summarized financial information of the Company’s investment in Altamira Medica:

	December 31,
	2023
Current assets		1,793,690
Non-current assets		-
Current liabilities		(897,665	)
Non-current liabilities		(989,411	)
Equity		(93,386)
Company’s share in equity - 49%		(45,759)
Goodwill		2,463,071
Company’s carrying amount of the investment		2,417,312

The associate had no contingent liabilities or capital commitments as at December 31, 2023.

	Nov 22, 2023 to Dec 31, 2023
Revenue from contracts with customers		379
Cost of sales		(33,967	)
Operating expenses		(29,321	)
Finance costs		(15,732	)
Profit before tax		(78,641	)
Income tax expense		(2,087	)
Profit after tax		(80,728	)
Other comprehensive income		14,018
Total comprehensive income		(66,710	)
Company’s share of loss of associate for the period		(39,557	)

Loans (Details) - Schedule of Loans - CHF (SFr)	12 Months Ended
Loans (Details) - Schedule of Loans - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Loans Abstract
Convertible loan February 2022		SFr 4,898,377
Loans with warrants		871,420
Short-term loan from related party		100,000
Total		SFr 5,869,797

Prepayments (Details) - Schedule of Prepayments - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Prepayments [Abstract]
Advance payments to suppliers	SFr 212,579	SFr 659,861
Insurance	71,253	49,405
Total prepayments	SFr 283,832	SFr 709,266

Loans (Details)												1 Months Ended	12 Months Ended
Loans (Details)	Dec. 15, 2023 shares	Dec. 07, 2023 SFr / shares	Jul. 10, 2023 shares	May 12, 2023 SFr / shares	May 12, 2023 SFr / shares	May 12, 2023 $ / shares	May 04, 2023	May 01, 2023 CHF (SFr) SFr / shares	Sep. 09, 2022 CHF (SFr) SFr / shares shares	Feb. 08, 2022 CHF (SFr)	Mar. 04, 2021 CHF (SFr)	Dec. 28, 2022 CHF (SFr) SFr / shares shares	Dec. 31, 2023 CHF (SFr) SFr / shares shares	Dec. 24, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 24, 2022 CHF (SFr)	Dec. 24, 2021 CHF (SFr)
Loan [Line items]
Pricing of conversion description													the 2022 FiveT Loan (see below), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire 2022 FiveT Loan into an aggregate of 217,050 common shares at an average conversion price of $28.95 per share (CHF 25.69 per share). As a result, the 2022 FiveT Loan is no longer outstanding and has been terminated. The fair value of the embedded derivative in the 2022 FiveT Loan as of December 31, 2022, was zero.
Derivative financial instruments													SFr 181,258	SFr 181,258
Convertible loan agreement amount								SFr 2,500,000	SFr 600,000			SFr 350,000
Interest rate								10.00%	5.00%			5.00%
Convertible Loan Agreement								22 months
Percentage of convertible loan								4.99%
Conversion price per share (in Francs per share) \| SFr / shares								SFr 28.4
Common shares (in Shares) \| shares	81,274		555,556										81,274
Exercise price per common share (in Francs per share) \| SFr / shares		SFr 6.656											SFr 30.76
Cash Plus							3.00%
Weighted average percentage				90.00%	90.00%	90.00%	90.00%
Purchase of warrants (in Shares) \| shares									2,085			2,359
warrants exercise share (in Francs per share) \| SFr / shares									SFr 144			SFr 89.02
Issuance term									5 years			5 years
Outstanding loan amount											SFr 17.62
Equity amount									SFr 86,744			SFr 48,185
Carrying amount									561,062			SFr 305,873			SFr 4,898,377
Convertible loan per share (in Francs per share) \| SFr / shares					SFr 22.4
Percentage of weighted average price (in Dollars per share) \| $ / shares						$ 120
Common share per value (in Francs per share) \| SFr / shares				SFr 17.62
Convertible loan description													The convertible loan of CHF 5.0 million, as amended (the “2022 FiveT Loan”) carried interest at the rate of 10% per annum and was to mature on May 31, 2023. FiveT IM had the right to convert all or part of the 2022 FiveT Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT IM own no more than 4.9% of the common shares at any time. On April 13, 2023, the Company and FiveT IM entered into an amendment to the 2022 FiveT Loan (the “2022 FiveT Loan Amendment”), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire FiveT Loan into an aggregate of 217,051 common shares at an average conversion price of $28.95 per share.
Expected volatility													90.70%
Derivative amount										SFr 449,898					SFr 0
Fair value measurement													SFr 449,898
Transaction costs													SFr 807,593
Mr. Meyer lent [Member]
Loan [Line items]
Principal amount									SFr 200,000

Trade and Other Payables

12 Months Ended

Dec. 31, 2023

Trade and Other Payables [Abstract]

Trade and other payables

17. Trade and other payables

	December 31,		December 31,
	2023		2022
Trade accounts payable - third parties		413,111		4,767,940
Other		27,303		146,464
Total trade and other payables		440,414		4,914,404

Deferred Income (Tables)

12 Months Ended

Dec. 31, 2023

Deferred Income [Abstract]

Schedule of Deferred Income

	December 31,		December 31,
	2023		2022
Upfront payment		-		932,200
Total deferred income		-		932,200

Loans (Tables)

12 Months Ended

Dec. 31, 2023

Loans [Abstract]

Schedule of Loans

	December 31,		December 31,
	2023		2022
Convertible loan February 2022		-		4,898,377
Loans with warrants		-		871,420
Short-term loan from related party		-		100,000
		-		5,869,797

Schedule of Convertible Loan Agreement

Convertible loan agreements

	December 31,			December 31,
	2023			2022
As of January 1		4,898,377			-
Gross proceeds at disbursement date		2,500,000			5,000,000
Embedded derivative, separated		(435,023	)		(449,898	)
Transaction costs allocated to host		-			(10,236	)
Carrying amount at initial recognition		6,963,354			4,539,866
Repayment in cash		(285,562	)		-
Converted principal amount		(7,214,438	)		-
Accrued interest		-			447,945
Amortization		536,646			358,511
Total		-			5,346,322
Accrued interest balance of December 31		-			447,945
Convertible loan balance of December 31		-			4,898,377

Research and Development Expense (Details) - Schedule of Research and Development Expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Research and Development Expense [Abstract]
Pre-clinical projects	SFr 505,031	SFr 389,673	SFr 96,840
Clinical projects	128,717	67,096	63,757
Product and process development	364,392	199,225	164,684
Employee benefits and expenses	1,429,564	1,426,299	934,577
Patents and trademarks	414,718	155,589	333,519
Regulatory projects	59,531	34,098	32,564
Impairment intangible assets		12,338,837	1,529,929
Depreciation tangible assets			46,635
Other research and development expense	133,459	10,753
Total research and development expense	SFr 3,035,413	SFr 14,621,570	SFr 3,202,505

Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 AUD ($)
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 1,157,400	€ (110,632)	$ 218,261	€ (1,656,992)	$ 879,531
Trade and other payables [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(129,943)	(86,547)	(1,086,206)	(1,452,883)
Accrued expenses [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(91,355)	(26,737)	(220,616)	(299,435)
Cash and cash equivalents [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	7,637	2,652	1,791	3,462
Trade and other receivables [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 1,371,060		$ 1,523,292	€ 91,864	$ 879,531

Segment Information

12 Months Ended

Dec. 31, 2023

Segment information [Abstract]

Segment information

6. Segment information

Geographical information

The Company’s non-current assets by the Company’s country of domicile were as follows:

	December 31,		December 31,
	2023		2022
Switzerland		3,973,792		4,339,509
Australia		-		-
Total		3,973,792		4,339,509

Non-current assets for geographical information exclude financial instruments and investments in associated companies.

Right-of-Use Assets and Lease Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Right-of-use assets and lease liabilities [Abstract]

Schedule of Right-of-Use Assets and Lease Liabilities

	Office
Right-of-use assets	building			Total
At cost
As of January 1, 2022		594,436			594,436
Additions		-			-
Disposals		-			-
As of December 31, 2022		594,436			594,436
Additions		-			-
Remeasurement (revised lease term)		(246,413	)		(246,413	)
As of December 31, 2023		348,023			348,023

Accumulated depreciation
As of January 1, 2022		(29,722	)		(29,722	)
Charge for the year		(118,887	)		(118,887	)
Disposals		-			-
As of December 31, 2022		(148,609	)		(148,609	)
Charge for the year		(119,304	)		(119,304	)
Disposals		-			-
As of December 31, 2023		(267,913	)		(267,913	)

Net book value
As of December 31, 2022		445,827			445,827
As of December 31, 2023		80,110			80,110

Schedule of Low Value and Short-Term Lease Expenses

	December 31,		December 31,
Low value and short-term lease expenses	2023		2022
Expense related to short-term leases		6,600		6,001
Expense related to leases of low value assets				-
Total		6,600		6,001

Schedule of Lease Liabilities

	December 31,			December 31,
Lease liabilities	2023			2022
As of January 1		461,485			575,736
Additions		-			-
Interest expense		19,294			15,949
Repayment of lease liability		(134,707	)		(130,200	)
Remeasurement (revised lease term)		(246,413	)		-
As of December 31		99,659			461,485

thereof non-current		-			343,629
thereof current		99,659			117,856

Schedule of Maturities of Lease Liabilities

	December 31,			December 31,
Maturities of lease liabilities	2023			2022
Year 1		101,030			130,200
Year 2		-			130,200
Year 3		-			130,200
Year 4		-			97,650
Year 5
Undiscounted lease payments		101,030			488,250
Less: unearned interest		(1,371	)		(26,765	)
Total		99,659			461,485

Other Operating Income (Tables)

12 Months Ended

Dec. 31, 2023

Other Operating Income [Abstract]

Schedule of Other Operating Income

	2023		2022		2021
Income from Government grants		228,302		-		-
Other income		27,287		9,327		-
Total other operating income		255,589		9,327		-

Taxation (Details) - Schedule of Tax Effect Unrecognized Loss Carryforwards - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Tax Effect Unrecognized Loss Carryforwards [Abstract]
Deferred income		$ 111,025
Employee benefit plan	45,200	43,841
Total potential tax assets	45,200	154,866
Potential tax assets from loss carry-forwards not recognized	7,936,946	13,297,723
Total potential tax assets from loss carry-forwards and temporary differences not recognized	$ 7,982,146	$ 13,452,589

Reporting Entity (Details)		12 Months Ended
Reporting Entity (Details)	Nov. 21, 2023	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 AUD ($)	Dec. 31, 2022 CHF (SFr)
Reporting Entity [Line Items]
Ownership percentage in subsidiary	51.00%
Share capital of subsidiary		SFr 2,646	$ 2,956			SFr 236,011
Investment equity percentage	49.00%	49.00%	49.00%	49.00%	49.00%
Spinning off percentage		51.00%
Auris Medical AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100.00%
Share capital of subsidiary		SFr 2,500,000
Otolanum AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100.00%
Share capital of subsidiary		SFr 100,000
Zilentin AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100.00%
Share capital of subsidiary		SFr 100,000
Altamira Therapeutics, Inc. [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100.00%
Share capital of subsidiary \| $			$ 100
Auris Medical Ltd. [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100.00%
Share capital of subsidiary \| €				€ 100
Auris Medical Pty Ltd [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		49.00%
Share capital of subsidiary \| $					$ 100
Altamira Medica AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary	51.00%
Auris Medical Pty Ltd [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary	100.00%

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Right-of-Use Assets and Lease Liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Right-of-Use Assets and Lease Liabilities [Line Items]
Cost Beginning	SFr 594,436	SFr 594,436
Accumulated depreciation Beginning	(148,609)	(29,722)
Net Book Value Ending	445,827
Net Book Value Beginning	80,110	445,827
Additions
Remeasurement (revised lease term)	(246,413)
Disposals
Cost Ending	348,023	594,436
Charge for the year	(119,304)	(118,887)
Accumulated depreciation Ending	(267,913)	(148,609)
Office building [Member]
Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Right-of-Use Assets and Lease Liabilities [Line Items]
Cost Beginning	594,436	594,436
Accumulated depreciation Beginning	(148,609)	(29,722)
Net Book Value Ending	445,827
Net Book Value Beginning	80,110	445,827
Additions
Remeasurement (revised lease term)	(246,413)
Disposals
Cost Ending	348,023	594,436
Charge for the year	(119,304)	(118,887)
Accumulated depreciation Ending	SFr (267,913)	SFr (148,609)

Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

OneYear Vesting Period [Member] | Equity Incentive Plan 2023 [Member]

Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]

^[1]

USD 1.72 (2 year vesting) 1) USD 1.96 (3 year vesting) 1)

USD 2.92

USD 2.92

108.87%

2 and 3 years

OneYear Vesting Period [Member] | Equity Incentive Plan 2022 [Member]

4.90%

Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]

^[2]

USD 132.88 (1 year vesting) 2) USD 175.2 (2 year vesting) 2) USD 212.08 (3 year vesting) 2)

USD 356

USD 415.60

99.10%

1, 2 and 3 years

Two Year Vesting Period [Member] | Equity Incentive Plan 2023 [Member]

2.87%

Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]

^[2]

USD 6.674 (1 year vesting) 2) USD 10.918 (2 year vesting) 2) USD 12.82 (3 year vesting) 2)

USD 19.2

USD 19.2

111.23%

1, 2 and 3 years

Two Year Vesting Period [Member] | Equity Incentive Plan 2022 [Member]

4.37%

Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]

^[1]

USD 86.94 (2 year vesting) 1) USD 100.22 (3 year vesting) 1)

USD 149.6

USD 127.06

100.20%

2 and 3 years